

Unravelling The Role Of APOE4 In Vascular Dysfunction

P2-05

Krystal K. Laing^{1234*}, Audrey Chagnot¹²³, Beth Geary⁶, Tracy Farr^{1†}, Maria Valdes-Hernandez^{134†}, William Mungall¹, Ross Lennen¹, Nela Fialova¹²³, Solvig Becker¹²³, Francesca Chappell¹²³⁴, Joanna Wardlaw¹²³⁴, and Axel Montagne^{123*}

¹ UK Dementia Research Institute at the University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK ² British Heart Foundation – UK Dementia Research Institute Centre for Vascular Dementia Research, University of Edinburgh, UK ³ Institute for Neuroscience and Cardiovascular Research (INCR), Chancellor’s Building, University of Edinburgh, UK ⁴ Row Fogo Centre for Research into Ageing and The Brain, University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK ⁵ University of Aberdeen, Aberdeen, UK ⁶ UK DRI Proteomics Platform, University of Dundee



Scan Here for DOIs

KEY TAKE-AWAY: APOE4 reduces endothelial VEGFR2 signaling, driving vascular dysfunction and white matter injury; VEGFR2 represents a promising therapeutic target.

